Contribute Try STAT+ Today

Thanks to the rapid development of Covid-19 vaccines, nearly two-thirds of patient advocacy groups believe the pharmaceutical industry was effective at tackling the pandemic, boosting its reputation last year to the highest level in a decade. But at the same time, a majority of the groups also found that, besides research and development, drug makers were lacking in most other areas of operation.

Specifically, 62% of the groups believed the industry, as a whole, dealt effectively with the coronavirus. For this reason, half of the groups feel that drug companies now have an excellent or good reputation, according to the survey by PatientView, a research firm that canvassed 1,920 groups from 84 countries between November 2020 and February 2021. They rated the reputations of 48 drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.